News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
The true narrative for Pfizer (PFE) is not its recent top line earnings beat but the escalating structural tension between its required research spending and an impending revenue void. First quarter 2026 results showed an adjusted earnings per share of $0.75 on $14.5 billion in revenue. While these numbers exceeded consensus estimates, they mask a deeper profitability issue. The primary insight hiding within the earnings noise is that Pfizer is funding its future growth at the direct expense of
A Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech sees as a differentiated option for patients with persistent disease.
Operational revenue from Pfizer’s Covid vaccine Comirnaty and Paxlovid pill to treat the illness declined 59% and 63%, respectively.
FDA approves VEPPANU (vepdegestrant), the first PROTAC protein degrader therapy, for ER+/HER2-, ESR1-mutated advanced breast cancer. Pfizer and Arvinas co developed VEPPANU, targeting patients who face significant challenges with endocrine resistance. Phase 3 results for ELREXFIO in relapsed or refractory multiple myeloma report positive outcomes, strengthening Pfizer's oncology pipeline. For investors following NYSE:PFE, these oncology milestones arrive with the stock trading around $26.3...
Moby summary of Pfizer Inc.'s Q1 2026 earnings call
Pfizer Chief Executive Albert Bourla is battling impending expirations for some blockbuster-drug patents and the precipitous decline of the company's Covid franchise, but he has put a date on when the company will return to consistent growth: 2029. Bourla said Tuesday he expects Pfizer will post high-single-digit average revenue growth annually from 2029 through 2033. “Products are losing patents, and we have a clear line of sight on growth starting in '29,” Bourla said in an interview after the company reported better-than-expected first-quarter results.
Pfizer topped first-quarter expectations, reaffirmed 2026 guidance, and faces pressure to prove future growth beyond Covid products.
May 5 (Reuters) - Pfizer said on Tuesday that it expects to return to stronger growth after 2028, driven by obesity drugs in development, a patent extension for its heart drug Vyndamax and a favorable European court ruling on its COVID-19 vaccine. The New York-based drugmaker also beat Wall Street expectations for first-quarter revenue and profit, buoyed by strong demand for its blood thinner Eliquis and recently acquired products, as it faces looming patent expirations and fading COVID produ
Pfizer beats Q1 estimates as new launches and acquired drugs lift sales, offsetting COVID declines, while the drugmaker reaffirms its 2026 outlook.
Pfizer Inc (NYSE:PFE, XETRA:PFE) reported first-quarter 2026 revenue and adjusted profit above Wall Street expectations on Tuesday, driven by strong growth in its launched and acquired products, as the drugmaker reaffirmed its full-year financial outlook. The pharmaceutical giant posted...
Raising capital while still building the data needed to validate an idea is often one of the biggest hurdles for start-ups.
All three major US stock indexes were up in late-morning trading Tuesday, as oil prices slid despite
Pfizer Inc. (NYSE:PFE) reported first-quarter results that came in ahead of Wall Street forecasts, supported by strong momentum in its recently launched and acquired product portfolio.
Pfizer's (PFE) first-quarter results surpassed analysts' estimates as robust demand across its key b
Early trading behaves as if cooler heads will prevail in the Strait of Hormuz -- and earnings results still matter.
BioNTech (NASDAQ:BNTX) executives used the company’s first-quarter 2026 earnings call to highlight a strategy centered on combination oncology therapies, provide updates on late-stage clinical programs, and outline capital allocation plans that include a $1 billion ADS share repurchase program and m
The Nasdaq Composite (^IXIC) opened higher Tuesday, with the tech-heavy benchmark riding a familiar trio of tailwinds: a fresh wave of strong earnings, a sharp pullback in crude oil, and a pause in Middle East escalation. Risk appetite is back, and the Nasdaq Composite (^IXIC) is riding the bullish wave. Google parent company Alphabet (Nasdaq: GOOGL), ... Alphabet, Intel, Micron Lead Nasdaq Higher as Oil Drops on Paused Mideast Tensions
The German biotech is struggling to redefine itself post-Covid, and an oncology push is part of the solution.
Although the revenue and EPS for Pfizer (PFE) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
The S&P 500 (^GSPC) heads into Tuesday with momentum after a powerful rebound last month in which the broader markets advanced 9%. A pullback in crude oil and first-quarter earnings beats are driving today’s gains as the markets embrace a reprieve in the Mideast escalation. The S&P 500 (^GSPC) is capturing those tailwinds for gains ... S&P 500 Rises on Big Tech Bump, Corporate Profits and Oil Price Relief
Pfizer stock edged higher early Tuesday on stronger-than-expected first-quarter sales and earnings. The company kept its outlook.
Higher sales of cancer treatments helped fuel better-than-expected first-quarter sales and profit for the drugmaker.
Revenue reached $14.45 billion, up 5% year-over-year, as oncology and other recently launched products offset steep declines in COVID products
Global pharmaceutical company Pfizer (NYSE:PFE) announced better-than-expected revenue in Q1 CY2026, with sales up 5.4% year on year to $14.45 billion. On the other hand, the company’s full-year revenue guidance of $61 billion at the midpoint came in 0.6% below analysts’ estimates. Its non-GAAP profit of $0.75 per share was 3.9% above analysts’ consensus estimates.
Pfizer CEO Albert Bourla and Accenture CEO Julie Sweet discuss how they’re using AI to transform their work. Watch the full episode of The 1 on 1 with CNN at CNN.com/the1on1.
Pfizer (PFE) delivered earnings and revenue surprises of +5.63% and +4.56%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Investing.com -- Pfizer Inc. (NYSE:PFE) reported first-quarter earnings that exceeded Wall Street expectations, driven by strong performance from its recently launched and acquired products portfolio.
The company said it would exit operations at some manufacturing plants in Germany and Singapore, and cut 1,860 positions in total.